Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
NCT06305754Phase 3Active, not recruiting
- Lead sponsor
- Merck Sharp & Dohme LLC (Industry)
- Enrollment
- 550 (estimated)
- Start date
- 11 Jun 2024
- Primary completion
- 17 Aug 2028 (estimated)
- Study completion
- 14 Jun 2030
- Last update posted
- 30 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Single
- Arms
- 2
Interventions
- Sacituzumab tirumotecan Biological
- Pemetrexed Drug
- Carboplatin Drug
- H1 Receptor Antagonist Drug
- H2 Receptor Antagonist Drug
- Acetaminophen (or equivalent) Drug
- Dexamethasone (or equivalent) Drug
- Steroid Mouthwash (dexamethasone or equivalent) Drug
Conditions and primary outcome
- Non-small Cell Lung Cancer (NSCLC)
Primary outcome
Overall Survival (OS) (Up to approximately 51 months)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT06305754.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06305754 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.